Utilizing IPA for the Discovery and Development of New Pain Therapeutics
Learn how Dr. Prysak utilized IPA to investigate the neuropathic pathways related to pain. In the United States, more than 39 million people suffer from neuropathic pain related to postherpetic neuralgia, trigeminal neuralgia, AIDS-related neuropathy, diabetic neuropathy, chronic low back pain, and cancer neuropathy. Unfortunately, neuropathic pain is often intractable and resistant to available drug therapies, none of which achieve clinical significance greater than 50%. To address this problem of great clinical need and poor therapeutic response, new mechanisms of action must be identified for future pain therapeutics. Aestus Therapeutics has undertaken a project to identify novel biological pathways involved in neuropathic pain using genome-wide expression data from a variety of sources and models. IPA, as well as other bioinformatics tools, helped Aestus identify seven novel biological pathways previously not associated with neuropathic pain. These seven novel pathways are being targeted for novel pain therapies. These potential therapeutics have been pre-clinically tested in animal models, validating both the pathways and the targets. The lead compound for the project, ATx08-001, was recently advanced into the clinic by Aestus, and is currently in a Phase 2 trial for the treatment of post-herpetic neuralgia. In this presentation, you will see how IPA was used to filter and explore existing data to investigate affected pathways and ultimately pathways for novel neuropathic pain therapies for patients.